Payment overview · 2025
General Payments
$435.35
19 reported records · 12 companies
Healthcare provider profile · identity verified
Erick Huarcaya, MD
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1245379288
Verified facts
What the public records show
CMS Open Payments records show Erick Huarcaya, MD received $435.35 in general payments during 2025 across 19 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Kerendia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $95.30 | 21.9% | 4 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $64.18 | 14.7% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $50.06 | 11.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.73 | 9.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.67 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.65 | 7.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.64 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.27 | 5.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.88 | 5.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.82 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.99 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.35 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $95.30 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $50.06 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 60 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
60 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 161 |
| Metformin Hcl | Metformin Hcl | 225 | 109 |
| Lisinopril | Lisinopril | 204 | 84 |
| Losartan Potassium | Losartan Potassium | 197 | 79 |
| Gabapentin | Gabapentin | 185 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 70 |
| Farxiga | Dapagliflozin Propanediol | 160 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 71 |
| Alendronate Sodium | Alendronate Sodium | 150 | 66 |
| Ibuprofen | Ibuprofen | 117 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 35 |
| Jardiance | Empagliflozin | 104 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 48 |
| Trazodone Hcl | Trazodone Hcl | 98 | 35 |
| Azithromycin | Azithromycin | 95 | 86 |
| Famotidine | Famotidine | 90 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 40 |
| Furosemide | Furosemide | 78 | 32 |
| Omeprazole | Omeprazole | 70 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 29 |
| Methocarbamol | Methocarbamol | 62 | 27 |
| Simvastatin | Simvastatin | 62 | 27 |
| Kerendia | Finerenone | 60 | 20 |
| Prednisone | Prednisone | 60 | 49 |
| Ozempic | Semaglutide | 54 | 18 |
| Metformin Hcl Er | Metformin Hcl | 52 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 24 |
| Sertraline Hcl | Sertraline Hcl | 51 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 21 |
| Glipizide | Glipizide | 42 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 19 |
| Celecoxib | Celecoxib | 39 | 14 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 30 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Trulicity | Dulaglutide | 35 | 15 |
| Fenofibrate | Fenofibrate,micronized | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 12 |
| Chlorthalidone | Chlorthalidone | 33 | 13 |
| Finasteride | Finasteride | 33 | 14 |
| Glimepiride | Glimepiride | 33 | 16 |
| Atenolol | Atenolol | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 14 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 15 |
| Allopurinol | Allopurinol | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 11 |
| Potassium Chloride | Potassium Chloride | 26 | 11 |
| Carvedilol | Carvedilol | 25 | 11 |
| Ketoconazole | Ketoconazole | 25 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | 14 |
| Montelukast Sodium | Montelukast Sodium | 25 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | 11 |
| Linzess | Linaclotide | 24 | 11 |
| Meloxicam | Meloxicam | 24 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Meclizine Hcl | Meclizine Hcl | 23 | 17 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | 12 |
| Ondansetron Odt | Ondansetron | 21 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Colchicine | Colchicine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | 11 |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Eliquis | Apixaban | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | 11 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.35 · 19 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Dexcom G6 Transmitter, INJECTAFER, INSPIRE, JOURNAVX, Kerendia, NURTEC ODT, OTEZLA, RECORLEV, REPATHA, REXULTI, YUPELRI, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error